Discover Merck's groundbreaking patent for ActRII-binding proteins, including innovative antibodies for diagnosing and treating muscle wasting, cancer, and more.
BYM388 – also known as bimagrumab – is an antibody targeting the myostatin/Activin type II receptor (ActRII) pathway and has been given a breakthrough designation by the US FDA for IBM.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results